| Assessment of response to transcatheter arterial chemoembolization with doxorubicin-eluting microspheres: tumor biology and hepatocellular carcinoma recurrence in a 5-year … TA Sandow, SE Arndt, AA Albar, DA DeVun, DS Kirsch, JM Gimenez, ... Radiology 286 (3), 1072-1083, 2018 | 43 | 2018 |
| Cyclin D1 in the liver: role of noncanonical signaling in liver steatosis and hormone regulation KG Núñez, J Gonzalez-Rosario, PT Thevenot, AJ Cohen Ochsner Journal 17 (1), 56-65, 2017 | 21 | 2017 |
| Complement activation in liver transplantation: role of donor macrosteatosis and implications in delayed graft function K Núñez, P Thevenot, A Alfadhli, A Cohen International Journal of Molecular Sciences 19 (6), 1750, 2018 | 15 | 2018 |
| Interleukin-33/Cyclin D1 imbalance in severe liver steatosis predicts susceptibility to ischemia reperfusion injury KG Núñez, A Frank, J Gonzalez-Rosario, G Galliano, K Bridle, D Crawford, ... PLoS One 14 (4), e0216242, 2019 | 8 | 2019 |
| Hypoalbuminemia is a hepatocellular carcinoma independent risk factor for tumor progression in low-risk bridge to transplant candidates KG Núñez, T Sandow, J Patel, M Hibino, D Fort, AJ Cohen, P Thevenot Cancers 14 (7), 1684, 2022 | 7 | 2022 |
| SLAMF1 is expressed and secreted by hepatocytes and the liver in nonalcoholic fatty liver disease O Gomez-Torres, S Amatya, L Kamberov, HA Dhaibar, P Khanna, O Rom, ... American Journal of Physiology-Gastrointestinal and Liver Physiology 323 (3 …, 2022 | 6 | 2022 |
| Baseline Alpha-Fetoprotein, Alpha-Fetoprotein-L3, and Des-Gamma-Carboxy Prothrombin Biomarker Status in Bridge to Liver Transplant Outcomes for Hepatocellular Carcinoma K Núñez, T Sandow, D Fort, J Patel, M Hibino, I Carmody, A Cohen, ... Cancers 13 (19), 2021 | 6 | 2021 |
| PD-1 expression in hepatocellular carcinoma predicts liver-directed therapy response and bridge-to-transplant survival KG Núñez, T Sandow, D Fort, M Hibino, P Wright, AJ Cohen, PT Thevenot Cancer Immunology, Immunotherapy, 1-13, 2022 | 4 | 2022 |
| Impaired autophagy response in Hepatocellular Carcinomas enriches glypican-3 in exosomes, not in the microvesicles AR Koksal, P Thevenot, Y Aydin, K Nunez, T Sandow, K Widmer, L Nayak, ... Journal of Hepatocellular Carcinoma, 959-972, 2022 | 4 | 2022 |
| Links between donor macrosteatosis, interleukin-33 and complement after liver transplantation K Núñez, M Hamed, D Fort, D Bruce, P Thevenot, A Cohen World Journal of Transplantation 10 (5), 117, 2020 | 2 | 2020 |
| Distinct Gene Expression Profiles in Viable Hepatocellular Carcinoma Treated With Liver-Directed Therapy KG Núñez, T Sandow, MA Lakey, D Fort, AJ Cohen, PT Thevenot Frontiers in Oncology 12, 809860, 2022 | 1 | 2022 |
| Glypican-3 enriched in exosomes not in the microvesicles: A potential biomarker for hepatocellular carcinoma AR Koksal, Y Aydin, D Lin, K Nunez, P Thevenot, MA Parsi, AJ Cohen, ... Hepatology 74, 691A-692A, 2021 | 1 | 2021 |
| Pre-treatment lymphocyte status in HCC patients associates with DEB-TACE response and correlates with liver synthetic dysfunction and increased regulatory immune cells K Nunez, T Sandow, M Hibino, P Thevenot, A Cohen Transplantation 105 (8), 39-39, 2021 | 1 | 2021 |
| Abstract No. 255 Single-System Outcomes Using 90-Yittrium Radioembolization as a Primary, Definitive Treatment Approach for Early-to Intermediate-Stage Hepatocellular Carcinoma A Zamani, K Nunez, T Sandow, J Gimenez, A Cohen, P Thevenot Journal of Vascular and Interventional Radiology 35 (3), S112, 2024 | | 2024 |
| Abstract No. 163 Liver-Directed Therapy Modality-Specific Outcomes Controlling for Index Tumor Size in Early-to Intermediate-Stage Hepatocellular Carcinoma A Zamani, K Nunez, T Sandow, J Gimenez, A Cohen, P Thevenot Journal of Vascular and Interventional Radiology 35 (3), S73, 2024 | | 2024 |
| Single system outcomes using 90-Yittrium radioembolization as a primary, definitive treatment approach for early-to intermediate-stage hepatocellular carcinoma A Zamani, K Nunez, T Sandow, J Gimenez, A Cohen, P Thevenot The American Journal of the Medical Sciences 367, S342, 2024 | | 2024 |
| Utilization of FIB-4 for progression risk in MASH-HCC following liver-directed therapy in BCLC A/B patients AG Troyer, K Nunez, T Sandow, J Gimenez, A Cohen, P Thevenot The American Journal of the Medical Sciences 367, S340-S341, 2024 | | 2024 |
| Imaging Delay Following Liver-Directed Therapy Increases Progression Risk in Early-to Intermediate-Stage Hepatocellular Carcinoma J Stanneart, KG Nunez, T Sandow, J Gimenez, D Fort, M Hibino, ... Cancers 16 (1), 212, 2024 | | 2024 |
| Single-Center 90Yttrium Outcomes in Early-Intermediate Stage Hepatocellular Carcinoma A Zamani, K Nunez, T Sandow, J Gimenez, A Cohen, P Thevenot American Journal of Transplantation 24 (1), S56-S56, 2024 | | 2024 |
| α-Fetoprotein, α-Fetoprotein-L3, and Des-γ-Carboxy Prothrombin Stratify Hepatocellular Carcinoma Treatment Response and Progression Risk K Núñez, M Schneider, T Sandow, J Gimenez, M Hibino, D Fort, A Cohen, ... Gastro Hep Advances 3 (3), 316-325, 2024 | | 2024 |
